R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Proceedings ArticleDOI
Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC)
Angela DeMichele,James J. Harding,Melinda L. Telli,Pamela N. Munster,Rana R. McKay,Othon Iliopoulos,Samuel H. Whiting,KW Orford,Mark K. Bennett,James W. Mier,Taofeek K. Owonikoko,Patel,K Kalinsky,Richard D. Carvajal,J. R. Infante,F Merit-Bernstam +15 more
TL;DR: The Pac-CB combination has been well tolerated and has demonstrated clinical activity in heavily pre-treated pts with TNBC, and the best overall response rate (BORR) has been PR in 20% (3 pts), SD in 47% (7 pts) and PD in 33% (5 pts) with 5 patients remaining on study.
Journal ArticleDOI
The promise and pitfalls of the many methods of plasma genotyping.
TL;DR: Although CTC analysis has a potential role in multiple tumor types, the development of these technologies has been slow, with limited clinical application to date, and this review will focus primarily on the application of cfDNA-based plasma genotyping.
Book ChapterDOI
Use of antibody arrays to probe exosome and extracellular vesicle mediated functional changes in cells.
TL;DR: The studies on the use of antibody arrays to probe for protein expression changes in hepatocytes that result from treating these cells with exosomes derived from uveal melanoma cells are described.
Journal ArticleDOI
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
Siqing Fu,Shuyang Yao,Yuan Yuan,Rebecca A. Previs,Anthony D. Elias,Richard D. Carvajal,Thomas J. George,Ying Yuan,Lihou Yu,Shannon N. Westin,Yan Xing,Ecaterina Elena Dumbrava,Daniel D. Karp,Sarina Anne Piha-Paul,Apostolia Maria Tsimberidou,Jordi Rodon Ahnert,Naoko Takebe,Karen H. Lu,Khandan Keyomarsi,Funda Meric-Bernstam +19 more
TL;DR: In this article , the authors conducted a phase II study to assess the antitumor activity of adavosertib in patients with CCNE1-amplified, advanced refractory solid tumors.